The FDA has expanded the approval of Yuflyma (adalimumab-aaty) and its unbranded version to include the treatment of HS in patients aged 12 years and older and UV in pediatric patients aged 2 years ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback